Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear fragile X mental retardation-interacting protein 2 (NUFIP2) is a ubiquitously expressed, non-canonical RNA-binding protein that interacts strongly with Roquin family proteins and is involved in post-transcriptional regulation of specific mRNA species, such as those encoding the T cell costimulatory molecule ICOS and the receptor OX40[1][3][4][5][6]. NUFIP2 localizes to cytoplasmic stress granules, nuclear bodies, and ribosomes, and its interaction with Roquin proteins enhances recognition and regulation of certain mRNA targets involved in immune cell function[1][2][3][4]. NUFIP2 also interacts with the fragile X mental retardation protein (FMRP), and competition between FMRP and Roquin for NUFIP2 likely influences mRNA decay pathways[1][3]. While associated genetically with neurodevelopmental and brain malformation syndromes, NUFIP2 is not recognized as a classical therapeutic target, nor are there approved drugs targeting its activity[4][5][6].
None reported for direct drug targeting
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear fragile X mental retardation-interacting protein 2 (NUFIP2).